Many provinces include IVF technology into medical insurance, and the auxiliary reproductive track ushered in a new air outlet

China Times (chinatimes.net.cn) reporter Guo Yilin Yu Na Beijing reporting

Population problems are always a major issue facing the development of a country.

A few days ago, FROST SULLIVAN (referred to as: Shalvin) released the "White Paper on the current Status and Future Development of the Industrial Industry in China" (hereinafter referred to as the White Paper). Therefore, the system analyzes the popular track of auxiliary reproduction, and focuses on the key link of reproductive health testing for the first time.

According to the "Bulletin of the National Economic and Social Development of 2021" issued by the National Bureau of Statistics, in 2021, 10.62 million people were born in 2021, 10.14 million deaths, and a net increase of 480,000. Beijing, Jiangxi, Hunan, Sichuan, Hubei and other places have also released news that it intends to include assisted reproductive technology projects into medical insurance. With the decline of the birth population, my country is rapidly entering the "aging society."

At the same time, in recent years, the government has paid more attention to this issue. Various policies that stimulate the birth of the population have emerged endlessly, and have issued fertility support policies in many places to include IVF costs into medical insurance. As the auxiliary reproductive related technologies are included in medical insurance, the auxiliary reproductive track has attracted more and more attention.

In response, Maohua, a partner and managing director of the Shalvin Greater China, accepted an interview with the "Huaxia Times" reporter, "With the development of technology, the auxiliary reproduction brings dawn to the infertile couple, while the reproductive health test is It is conducive to reducing birth defects and achieving eugenics. Auxiliary reproduction as the application of modern medical technology in responding to the national population issue is in the ascendant; reproductive health testing is an important means to improve the quality of population and prevent and control birth defects.

Industry heat up

In recent years, whether it is the development of medical technology or the active implementation of the "second child" or even "three -child" population, it has shown that the fertility problem has risen to the national strategic height.

On July 20, 2021, the "Decision of the Central Committee of the Communist Party of China and the State Council on Optimizing the Breakfast Development of Population Powers" was announced to the public. Strict technical approval, build a human assisted reproductive technology service system with a balanced supply and demand and reasonable layout "

As the "two sessions" ended in 2022, the discussion on fertility issues continued to this day. Among them, the auxiliary reproduction as the application of modern medical technology in response to the national population issue, and its development and prospects have continued to be concerned and discussed.

In fact, in many countries in the world, the accessibility and quality of infertility intervention measures are still a major challenge. The diagnosis and treatment of infertility are often not listed as a priority of national population and development policies and reproductive health strategies, and rarely receive public health support.

However, with the increasing number of infertility people, the voices of incorporating auxiliary reproductive technology including IVFs have become increasingly rising. Happiness said, "China's auxiliary reproductive penetration rate is far lower than other developed regions of the world, but the growth rate is fast. Under the effect of multiple driving factors such as the increase in the demand of the auxiliary reproductive demand and the increase in technology, the gap between the penetration rate of developed countries has gradually reduced. The most effective auxiliary reproductive technology for treatment of infertility, in vitro fertilization IVF has formed a relatively complete detection and treatment process, occupying an important position in the auxiliary reproductive market. "

Policy assistance blessing

It is not difficult to see from the change of the attitude of the State Medical Insurance Bureau that the auxiliary reproduction entering the medical insurance is moving in a good direction.

In September 2020, when the National Medical Insurance Bureau responded to "suggestions on incorporating the cost of auxiliary maternity diagnosis and treatment into medical insurance", it was said that it did not have the conditions to include the auxiliary reproductive technology into the scope of basic medical insurance payment.

In August 2021, the State Medical Insurance Bureau proposed that eligible fertility support drugs, Topurerin, deingmane and other ovulation -promoting drugs were included in the payment scope. At the same time, it will guide all places to gradually incorporate the technical, safe, reliable, and controllable therapeutic reproductive technology that the medical insurance capacity can bear in accordance with procedures into the scope of medical insurance payment according to procedures.

After that, Beijing, Jiangxi, Hunan, Sichuan, Hubei and other places also released news that it intends to include assisted reproductive technology projects into medical insurance. In February 2022, the Beijing Municipal Medical Insurance Bureau, together with the Municipal Health and Health Commission and the Municipal Human Resources and Social Affairs Bureau, issued the "Notice on Regulating and Adjusting Some Medical Service Price Projects", which is currently undergoing overall research by the State Medical Insurance Bureau and implemented after determining. While regulating the price of the auxiliary reproductive medical service projects, this policy will first have 16 items including artificial fertilization, embryo transplantation, and preferred sperm treatment in the clinic treatment for the first time. Reliable auxiliary reproductive technology projects are included in the scope of medical insurance category.

In March 2022, the Jiangxi Provincial Medical Security Bureau officially issued the "Notice on Adjusting the Category of Medical Insurance Payment of Medical Service Projects" and other medical service projects such as "postoperative analgesia". From March 8th, Jiangxi will include "painless delivery" into the reimbursement scope. You can use the medical insurance card to swipe the card to settle.

Maohua believes that "after incorporating the auxiliary reproduction into the medical insurance, it can not only effectively break the conceptual gap and solve the needs of patients with infertility in my country. Secondly, after entering the medical insurance The auxiliary reproductive industry is conducive to the continuous innovation and progress of technology. The research and development of new drugs and medical devices provides capital guarantee for the development of auxiliary reproductive technology, improves the market penetration rate of the auxiliary reproductive, and is conducive to improving the industry's prosperity. "A blue ocean

As an emerging market that assisted reproduction, my country has maintained a high growth rate in recent years.

According to Shalvin's data, by 2023, the proportion of infertility people in my country will reach 18.2%, and the demand for assisting reproduction will be further increased. The Institute of Open Source Securities Institute calculated that the compound rate of 2018-2023 was 9.64%. By 2023, the size of the auxiliary reproductive market was expected to increase to 40 billion yuan, which is expected to exceed 100 billion in a long time.

Therefore, the potential capacity of the reproductive health testing market is considerable, and it is still a blue ocean. As of now, Shalvin statistics believe that China's reproductive health testing potential market covers approximately 40 million pregnant couples, so as to estimate the potential of the chromosome testing market can exceed 55 billion yuan; in the future, the scope of testing is expected to expand, and even potential can be extended to China to my country Nearly 300 million nursery population is a test as its routine.

"The reproductive health testing industry has initially formed a complete industrial chain in my country; but the degree of localization of the upstream hardware of the industry is low, and the large -scale and high -quality conventional testing services have not been carried out. The increase in burden has shown a trend of increasing the auxiliary reproductive certificate agency in recent years. "Maohua analyzed to reporters.

Not only that, reproductive health testing has a profound impact on national birth defect prevention and control and eugenics. In my country, birth defects are currently the main causes of early abortion, death, death, infant death, and congenital disability. In order to reduce the serious burden of birth defects to the people and society, my country has vigorously promoted the first, second, and third -level prevention and control measures for birth defects. First -level prevention and control, as a means to fundamentally alleviate the problem of birth defects, is expected to be promoted rapidly.

Chromosomal abnormalities are important causes of severe newborn birth defects. The latest real -world data shows that the incidence of abnormalities in chromosomes in China has exceeded 1%; and reproductive health tests such as chromosome nuclear testing can help investigate this situation, which can help discover some fetal risks of high -rate risks. Re -fertilized cultivation before embryonic transplantation. Such testing in routine to the age population is not only of great significance to individual health and family happiness, but also greatly develops the health and sustainable development of the population quality and socioeconomic and social economy of the entire country.

For a long time, my country's reproductive health test has faced pain points such as high detection costs, low hospital penetration, insufficient detection sensitivity, and difficulty guarantee for national genetic information security; Happening. With the improvement of technological level, R & D innovation and product update iteration is not only an effective means to effectively solve the above pain points, but also an important driving force for industry progress.

Editor -in -chief: Editor of Sun Mengyuan: Chen Yanpeng

- END -